# A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Volunteers to Evaluate Accelerated Vaccine Schedules

> **NCT00001076** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 34 (—)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** ALVAC-HIV MN120TMG (vCP205)
- **BIOLOGICAL:** ALVAC-RG Rabies Glycoprotein (vCP65)
- **BIOLOGICAL:** rgp120/HIV-1 SF-2

## Key facts

- **NCT ID:** NCT00001076
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 1997-12
- **Target enrollment:** 34 (—)
- **Last updated:** 2021-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001076, "A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Volunteers to Evaluate Accelerated Vaccine Schedules". Retrieved via MORVS 2026-10-10 from https://api.morvs.ai/clinical/NCT00001076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*